Pieris Pharmaceuticals, Inc.

NasdaqCM:PIRS 株式レポート

時価総額:US$12.5m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Pieris Pharmaceuticals 過去の業績

過去 基準チェック /06

Pieris Pharmaceuticalsは1%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで15.5%毎年増加している。売上は減少しており、年平均3%の割合である。

主要情報

1.0%

収益成長率

11.0%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率-3.0%
株主資本利益率-74.0%
ネット・マージン-39.7%
前回の決算情報31 Mar 2024

最近の業績更新

Recent updates

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Apr 21
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Mar 19
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

Dec 18
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Aug 18
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

May 15
Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Apr 17
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Dec 31
Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Aug 10
Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M

Aug 04

Pieris: Early Stage Developer Of Novel Asset Class

Jan 09

We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Dec 15
We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Progress At Pieris Pharmaceuticals

Oct 27

Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

Aug 05
Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 19
We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

May 22
Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

May 19
Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Apr 01
Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

Mar 08
Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Feb 01
We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Dec 28
How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

Dec 02
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

収支内訳

Pieris Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqCM:PIRS 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 2441-16170
31 Dec 2343-25170
30 Sep 2347-28190
30 Jun 2333-27160
31 Mar 2317-41160
31 Dec 2226-33160
30 Sep 2228-35160
30 Jun 2227-42170
31 Mar 2227-47170
31 Dec 2131-46170
30 Sep 2125-51160
30 Jun 2124-48160
31 Mar 2132-38160
31 Dec 2029-37170
30 Sep 2045-26180
30 Jun 2057-15180
31 Mar 2051-22180
31 Dec 1946-28180
30 Sep 1934-361913
30 Jun 1927-401824
31 Mar 1933-281934
31 Dec 1829-271841
30 Sep 1842-82133
30 Jun 1838-81928
31 Mar 1828-181824
31 Dec 1725-181822
30 Sep 1710-321423
30 Jun 177-311322
31 Mar 176-271121
31 Dec 166-23919
30 Sep 165-19915
30 Jun 165-17913
31 Mar 164-15810
31 Dec 153-1498
30 Sep 154-15107
30 Jun 154-1386
31 Mar 154-1396
31 Dec 145-1075
30 Sep 146-555
31 Dec 1312039

質の高い収益: PIRSは現在利益が出ていません。

利益率の向上: PIRSは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: PIRSは利益を出していないが、過去 5 年間で年間1%の割合で損失を削減してきた。

成長の加速: PIRSの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: PIRSは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。


株主資本利益率

高いROE: PIRSは現在利益が出ていないため、自己資本利益率 ( -73.99% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘